DHG Pharmaceutical JSC

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: VN000000DHG0
VND
100,400.00
2600 (2.66%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

High Management Efficiency with a high ROE of 20.35%

 
2

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 57.01

 
3

Poor long term growth as Net Sales has grown by an annual rate of 5.44% over the last 5 years

 
4

Flat results in Sep 25

5

With ROE of 22.34%, it has a fair valuation with a 3.50 Price to Book Value

6

Underperformed the market in the last 1 year

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

VND 13,492,995 Million (Mid Cap)

stock-summary
P/E

16.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

5.81%

stock-summary
Debt Equity

-0.53

stock-summary
Return on Equity

20.91%

stock-summary
Price to Book

3.23

Revenue and Profits:
Net Sales:
1,742,472 Million
(Quarterly Results - Dec 2025)
Net Profit:
184,797 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-0.59%
0%
-0.59%
6 Months
-3.92%
0%
-3.92%
1 Year
-18.37%
0%
-18.37%
2 Years
-20.44%
0%
-20.44%
3 Years
8.07%
0%
8.07%
4 Years
6.24%
0%
6.24%
5 Years
7.73%
0%
7.73%

DHG Pharmaceutical JSC for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
7.00%
EBIT Growth (5y)
4.06%
EBIT to Interest (avg)
57.01
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.47
Sales to Capital Employed (avg)
0.98
Tax Ratio
13.16%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
45.64%
ROE (avg)
20.35%

Valuation key factors

Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
3.50
EV to EBIT
12.00
EV to EBITDA
10.44
EV to Capital Employed
5.38
EV to Sales
2.37
PEG Ratio
5.59
Dividend Yield
9.86%
ROCE (Latest)
44.85%
ROE (Latest)
22.34%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 19.46% vs -4.96% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -11.24% vs -20.27% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,742,471.80",
          "val2": "1,458,678.30",
          "chgp": "19.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "340,264.60",
          "val2": "324,518.90",
          "chgp": "4.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2,999.00",
          "val2": "8,234.70",
          "chgp": "-63.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "184,797.10",
          "val2": "208,192.20",
          "chgp": "-11.24%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "127.30%",
          "val2": "184.30%",
          "chgp": "-5.70%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 7.82% vs -2.60% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 15.27% vs -25.91% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5,266,962.70",
          "val2": "4,884,867.70",
          "chgp": "7.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,104,730.10",
          "val2": "1,031,482.00",
          "chgp": "7.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "25,689.90",
          "val2": "24,886.20",
          "chgp": "3.23%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "868,648.80",
          "val2": "753,552.50",
          "chgp": "15.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "187.20%",
          "val2": "176.40%",
          "chgp": "1.08%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoYstock-summary

Dec'25
Dec'24
Change(%)
Net Sales
1,742,471.80
1,458,678.30
19.46%
Operating Profit (PBDIT) excl Other Income
340,264.60
324,518.90
4.85%
Interest
2,999.00
8,234.70
-63.58%
Exceptional Items
0.00
0.00
Consolidate Net Profit
184,797.10
208,192.20
-11.24%
Operating Profit Margin (Excl OI)
127.30%
184.30%
-5.70%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Dec 2025 is 19.46% vs -4.96% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -11.24% vs -20.27% in Dec 2024

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
5,266,962.70
4,884,867.70
7.82%
Operating Profit (PBDIT) excl Other Income
1,104,730.10
1,031,482.00
7.10%
Interest
25,689.90
24,886.20
3.23%
Exceptional Items
0.00
0.00
Consolidate Net Profit
868,648.80
753,552.50
15.27%
Operating Profit Margin (Excl OI)
187.20%
176.40%
1.08%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 7.82% vs -2.60% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 15.27% vs -25.91% in Dec 2024

stock-summaryCompany CV
About DHG Pharmaceutical JSC stock-summary
stock-summary
DHG Pharmaceutical JSC
Pharmaceuticals & Biotechnology
DHG Pharmaceutical Joint Stock Company is a Vietnam-based company engaged in the pharmaceutical industry. The Company manufactures and markets pharmaceutical products, vitamins, supplements and cosmetics. Via its subsidiaries, the Company is also involved in packaging printing, herb cultivation, medicinal supplies trading, as well as domestic travel tour and medical clinic operation.
Company Coordinates stock-summary
Company Details
288 Bis Nguyen Van Cu, P. An Hoa, Q. Ninh Kieu CAN THO None : None
stock-summary
Tel: 84 29 2389143384 292 3891433
stock-summary
Registrar Details